Literature DB >> 25002179

Risk factors for visual hallucinations in patients with Parkinson's disease.

Rômulo Lopes Gama, Veralice Meireles Sales de Bruin, Pedro Felipe Carvalhedo de Bruin, Daniel Gurgel Fernandes Távora, Emily Mourão Soares Lopes, Iago Farias Jorge, Lia Rita Azeredo Bittencourt, Sergio Tufik.   

Abstract

AIM: Parkinson's disease (PD) patients frequently present visual hallucinations (VHs) that have been associated with depression, old age, and cognitive impairment. Sleep abnormalities are also related to these factors. The aim of this study is to evaluate risk factors, particularly sleep alterations, associated with VHs in PD.
METHODS: This is a cross-sectional evaluation of consecutive patients from a Movement Disorder's clinics. Patients were clinically evaluated, and behavioral questionnaires were applied in a face-to-face interview.
RESULTS: Among 100 PD patients (67% male, mean age  =  65.0 ± 10.4), VHs were present in 28% of cases; individuals with VHs had worse sleep quality (Pittsburgh Sleep Questionnaire Index) and more severe sleep disturbances [Parkinson's Disease Sleep Scale (PDSS)]. Logistic regression analysis showed that vivid dreams and Unified Parkinson's Disease Rating Scale (UPDRS) I scores (i.e., mentation, behavior, and mood symptoms) are independently associated with VHs. Our data show that the presence of vivid dreams is associated with VHs in PD and reaffirm that VHs are linked to cognitive impairment.
CONCLUSIONS: Investigating vivid dreams may help the identification of VHs in PD. Identifying vivid dreams can be hard considering that patients may fail to report symptoms for the fear of the stigma associated with psychosis and dementia.

Entities:  

Keywords:  Mental dysfunction; Parkinson’s disease,; Sleep,; Visual hallucinations,; Vivid dreams,

Mesh:

Year:  2014        PMID: 25002179     DOI: 10.1179/1743132814Y.0000000418

Source DB:  PubMed          Journal:  Neurol Res        ISSN: 0161-6412            Impact factor:   2.448


  6 in total

Review 1.  Parkinson's disease psychosis: therapy tips and the importance of communication between neurologists and psychiatrists.

Authors:  Daniel Martinez-Ramirez; Michael S Okun; Michael S Jaffee
Journal:  Neurodegener Dis Manag       Date:  2016-07-13

Review 2.  Psychosis in Parkinson's disease: identification, prevention and treatment.

Authors:  Johannes Levin; Alkomiet Hasan; Günter U Höglinger
Journal:  J Neural Transm (Vienna)       Date:  2015-04-18       Impact factor: 3.575

Review 3.  Psychosis in Parkinson's Disease: Epidemiology, Pathophysiology, and Management.

Authors:  Anna Chang; Susan H Fox
Journal:  Drugs       Date:  2016-07       Impact factor: 9.546

Review 4.  The psychosis spectrum in Parkinson disease.

Authors:  Dominic H Ffytche; Byron Creese; Marios Politis; K Ray Chaudhuri; Daniel Weintraub; Clive Ballard; Dag Aarsland
Journal:  Nat Rev Neurol       Date:  2017-01-20       Impact factor: 42.937

5.  Atypical antipsychotic therapy in Parkinson's disease psychosis: A retrospective study.

Authors:  Mei Yuan; Laura Sperry; Norika Malhado-Chang; Alexandra Duffy; Vicki Wheelock; Sarah Farias; Kevin O'Connor; John Olichney; Kiarash Shahlaie; Lin Zhang
Journal:  Brain Behav       Date:  2017-04-14       Impact factor: 2.708

6.  Visual hallucinations in Parkinson's disease are associated with thinning of the inner retina.

Authors:  F Visser; V I Apostolov; A M M Vlaar; J W R Twisk; H C Weinstein; H W Berendse
Journal:  Sci Rep       Date:  2020-12-03       Impact factor: 4.379

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.